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Pulmonary concerns in liver transplant candidates have intraop-
erative and outcome implications. Evolving MELD exception pol-
icies address transplant priority for problems such as
hepatopulmonary syndrome, portopulmonary hypertension, and
hemorrhagic hereditary telangiectasia. Other pulmonary issues
such as refractory hepatic hydrothorax, advanced chronic
obstructive lung disease (including alpha-1 antitrypsin deﬁ-
ciency) and indeterminate pulmonary nodules may affect liver
transplant consideration. Herein, we discuss current pulmon-
ary-related contraindications, indications and MELD exception
policies for liver transplantation, suggesting future
considerations.
Severity and natural history of pulmonary abnormalities may
present increased, as well as unacceptable risk for liver transplan-
tation (LT), thus be considered contraindications to LT [1]. How-
ever, resolution of certain pulmonary disorders following LT
suggests these abnormalities may be appropriate pulmonary
indications for LT and should merit higher LT priority to prevent
morbidity and mortality [2]. With the inception of the Model of
End-Stage Liver Disease (MELD) score in 2002 to prioritizeJournal of Hepatology 20
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13, 2012) standardized MELD exception policy (http://optn.
transplant.hrsa.gov policy 3.6.4.5), the importance of selected
pulmonary issues has been magniﬁed. Therefore, it is instructive
to identify the spectrum of pulmonary abnormalities that pose
the greatest LT risk and their potential reversibility. The current
MELD exception policies (or lack thereof) concerning these pul-
monary issues are addressed and future pulmonary consider-
ations are suggested. The major pulmonary concerns that arise
in liver transplant candidates discussed in this contemporary
view are shown in Table 1.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Hepatopulmonary syndrome (HPS)
Documented in 4–32% of patients evaluated for LT, there is no
proven medical therapy to cure the arterial hypoxemia that char-
acterizes HPS [3]. A triad deﬁnes HPS:
(1) Portal hypertension with or without cirrhosis;
(2) Arterial hypoxemia due to;
(3) Intrapulmonary vascular dilatations (detected by contrast
echocardiography or 99mTc macroaggregated albumin
lung–brain perfusion scanning).
The diagnostic criteria for arterial hypoxemia vary by trans-
plant center and have been summarized by Schenk et al. [4] in
Table 2. Although initially considered an absolute contraindica-
tion to LT if hypoxemia was severe (PaO2 <50 mmHg), Laberge
et al. [5] were the ﬁrst to report resolution of HPS with LT (two
children) in 1992 and stated that LT ‘‘. . . may be an actual indica-
tion for earlier transplantation even with relatively stable liver
disease’’.
Numerous reports of HPS resolution post LT followed over the
ensuing years. Despite these successes, the risk of LT remained
signiﬁcant (15.6% post LT hospitalization mortality in 32 HPS
patients as reported from the 10-center liver transplant database)
[6]. Mortality was directly related to the pre-LT severity of hypox-
emia (PaO2: survivors 55 mmHg; non-survivors 37 mmHg).
Subsequently, the largest single-center analysis (61 HPS patients)13 vol. 59 j 367–374
Table 1. Major pulmonary concerns in liver transplant candidates.
Hepatopulmonary Syndrome (HPS)
Portopulmonary Hypertension (POPH)
Hemorrhagic Hereditary Telangiectasia (HHT)
High output cardiac failure due to intrahepatic vascular 
malformations
Pulmonary arteriovenous malformations
Refractory Hepatic Hydrothorax (HH)
Advanced Chronic Obstructive Pulmonary Disease (COPD)
Smoking-related emphysema
Alpha-1 Anti-Trypsin Deficiency (AATD)-related emphysema
Pulmonary nodules
Hepatocellular carcinoma metastases
Interstitial Lung Disease (ILD)
Associated with primary biliary cirrhosis, autoimmune liver 
disease, hepatitis C
Concomitant idiopathic pulmonary fibrosis
Table 2. Frequency of HPS using various deﬁnitions for arterial hypoxemia.⁄
Cut-off value for hypoxemia N centers
(No. of patients 
screened)
HPS (%)
PaO2
<60 mmHg 1 (98) 12
<70 mmHg 6 (277) 5-18
<80 mmHg 2 (135) 8-19
Alveolar-arterial oxygen gradient
>15 mmHg 3 (179) 19-32
>age threshold* 8 (356) 4-26
⁄Value calculation includes arterial PCO2 and is adjusted upwards (normal
>20 mmHg if age >64 years).
Modiﬁed from Schenk et al. [4].
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Fig. 1. Long-term outcome following liver transplantation in patients with
hepatopulmonary syndrome based upon their baseline PaO2 at the time of
diagnosis pre-transplant. No difference was observed between the PaO2 cut-offs.
Adapted from [12], reprinted with permission.
Reviewdocumented poor prognosis (5-year survival) in those not
transplanted (n = 24; 23%) vs. those transplanted (n = 37; 76%)
[7]. No correlation was noted between HPS severity and the
degree of hepatic dysfunction (by Child class or MELD score).
Discordance between liver disease severity and degree of hyp-
oxemia, combined with resolution of hypoxemia after LT,
resulted in HPS to be considered a standard indication for LT.
With the adoption of the MELD allocation system in 2002,
patients with HPS were often granted and assigned a priority
score which typically allowed them to receive a MELD score
exception, though this was done at the level of each individual
Organ Procurement and Transplantation Network (OPTN) Regio-
nal Review Board. However, HPS diagnostic criteria were not
standardized, fostering regional variation in scores, and the need
for further discussion [8–10]. To reduce this tremendous variabil-
ity, MELD exception policy was subsequently formalized (via the
MELD exception Study Group Conference in 2006) and revised so
that uniform assigned MELD score exception of 22 would be
granted across all regions if PaO2 was less than 60 mmHg (arterial
blood gas measured breathing room air, at rest and in the sitting
position) [10]. Those patients would have clinical evidence of
portal hypertension, demonstrated intrapulmonary vascular dila-
tation in the absence of underlying primary lung disease that368 Journal of Hepatology 201might account for hypoxemia. Currently, a standard MELD score
increase, which is a 10% wait list mortality equivalent, is granted
every 3 months if the repeat PaO2 remains less than 60 mmHg.
Recent HPS reports by Gupta et al. [11] (n = 21; no MELD
exception) and Iyer et al. [12] (n = 28; 21 granted MELD excep-
tion) have now clearly demonstrated that LT candidates with
severe hypoxemia (PaO2 <50 mmHg) have minimal waitlist mor-
tality, beneﬁt from improved ICU care, and experience HPS reso-
lution with long-term post LT survival. Eleven of 21 HPS patients
in the Gupta report had PaO2 <50 mmHg and 10 had survived 55–
1078 days (median 548) post LT. Iyer noted a 76% 5-year post LT
survival in 19/49 HPS patients with baseline PaO2 <50 mmHg
(Fig. 1). Importantly, there have been no reports of intraoperative
death due directly to the severity of HPS. There is consensus that
the more severe the pre-LT arterial hypoxemia, the longer the
post LT recovery in terms of resolving hypoxemia, potential mor-
bidity, and prolonged need for supplemental oxygen [3,13].
Clinical experience has resulted in the expectation that arte-
rial oxygenation due to HPS will normalize following LT, hence
the ‘‘indication’’ for LT. OPTN policy states that HPS patients
meeting speciﬁed criteria receive a standard MELD exception
every three months until time of transplant, as long as the patient
continues to meet criteria. The decision not to offer LT for those
with moderate to severe hypoxemia remains a local transplant
center determination based upon co-morbidities and expertise
available to manage post LT issues. Living donor LT in the setting
of HPS allows ﬂexibility in transplant timing and has been suc-
cessful in resolving the syndrome. Living donor LT eliminates
the need for MELD exception considerations [14].
Future considerations
With successful LT, severe hypoxemia due to HPS can resolve.
Current MELD exception guidelines state that no other pulmon-
ary abnormality should co-exist as a reason for hypoxemia. This
may be impractical and exclude HPS patients (noting up to 30%
may be excluded due some degree of COPD) that would other-
wise do well in the long term. Identifying the contribution to
hypoxemia from HPS vs. hypoxemia due to COPD, ILD or HH
can be accomplished using 99mTcMAA lung-brain scanning. Indi-
viduals with mild to moderate non-HPS pulmonary dysfunction3 vol. 59 j 367–374
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(with expected 5-year survival >75% associated with those
entities) would not be excluded from LT and attain long-term
overall survival.Portopulmonary hypertension (POPH)
Documented in 4.5–8.5% of liver transplant candidates, the diag-
nosis of POPH is based upon right heart catheterization [15]:
1. Mean pulmonary artery pressure – MPAP >25 mmHg;
2. Pulmonary capillary wedge pressure – PCWP <15 mmHg;
3. Pulmonary vascular resistance – PVR >240 dynes s cm5 (or 3
Wood units).
Not uncommon, POPH comprises up to 10% of all patients
referred to the French National Center for pulmonary artery
hypertension with outcomes related to the severity of cirrhosis
and cardiac function [16]. The controlled trials in idiopathic pul-
monary artery hypertension targeting pathways of prostacyclin
deﬁciency, endothelin receptor blockade, and phosphodiesterase
inhibition have documented signiﬁcant success in improving pul-
monary hemodynamics (all pathways) and survival (prostacyclin
pathway). Using similar approaches in POPH (pathway drugs
used alone or in combination during uncontrolled trials), the 5-
year POPH survival (n = 153) was reported to be 40% from the
multicenter REVEAL registry, despite having better hemodynam-
ics than the idiopathic pulmonary artery hypertension subgroup
[17] (Fig. 2). Survival in the French study (n = 154) was 68% at
5 years and may have reﬂected a lack of discerning severity and
type of hepatic disorders in the REVEAL registry. Without pul-
monary vasoactive medications or LT, a single-center 5-year
POPH survival has been reported to be 14% [18].
Resolution of severe POPH following LT was ﬁrst reported by
Yoshida et al. [19] in 1993 who utilized intravenous prostacyclin
pre-LT (MPAP = 45? 33 mmHg), intraoperatively, and for 3 days
post LT. At 22 months post LT, the MPAP as 22 mmHg, prostacy-
clin discontinued and the authors stated: ‘‘Our success . . . suggests
that a signiﬁcant reversible component exists in some cases of porto-
pulmonary hypertension’’.100
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Fig. 2. Five-year survival in patients with portopulmonary hypertension
compared to those with idiopathic pulmonary artery hypertension. Uncon-
trolled treatments in both groups. None with POPH underwent liver transplant.
aOnly patients enrolled within 5 years of diagnosis were included in the 5-year
survival from diagnosis curve. Adapted from [16], reprinted with permission.
Journal of Hepatology 201Unlike HPS, the outcomes of LT in the setting of POPH have
been unpredictable. Intraoperative death due to acute right heart
failure has occurred. The multicenter HPS and POPH database
(n = 36 POPH patients transplanted) reported pre-LT mean pul-
monary artery pressure (MPAP) >35 mmHg and pulmonary vas-
cular resistance (PVR >250 dynes s cm5) was associated with a
36% mortality (5 intraoperative; 8 transplant hospitalization),
all occurring within 18 days of transplant [6]. Subsequent case
reports and small series have documented resolution of POPH
or improvement with LT if pre-LT therapy with pulmonary vaso-
active medications could reduce MPAP to less than 35 mmHg
[15,20,21].
Due to the success of LT to resolve POPH, when pre-LT treat-
ments improved pulmonary hemodynamics and hope to reduce
pre-LT mortality, MELD exception was allowed for some POPH
patients by regional review boards beginning in 2002. A general
summary from the Scientiﬁc Registry of Transplant Recipients
(SRTR) identiﬁed outcomes in 155 patients granted POPH MELD
exception (2002–2012), but no speciﬁc data were available to
characterize the severity of POPH or pre-LT pulmonary hemody-
namic treatment results. Waitlist death rate was 7.8%; 1 and 3-
year survivals were 83% and 76%, respectively (T Leighton, SRTR,
personal communication).
Pulmonary hemodynamic criteria for MELD exception were
suggested in 2006 and formal criteria established in 2010 to
attain review board uniformity in granting standard MELD excep-
tion [22]. Currently, if MPAP can be improved to <35 mmHg and
PVR reduced to <400 dynes s cm5, then MELD exception is
granted, increasing by 10% every three months if repeat RHC
demonstrates sustained hemodynamic improvement.
Unlike HPS, the concept of POPH being an ‘‘indication for LT’’
remains controversial due to the variable outcomes of POPH fol-
lowing LT. Limited, but well-documented experience suggests
some patients are ‘‘cured’’ of the POPH (normalization of pulmon-
ary hemodynamics) after LT and pulmonary vasoactive medica-
tions can be safely discontinued [15,20,21]. Improving
pulmonary hemodynamics, to the point of allowing LT, is signif-
icant in that approximately 50% of patients with POPH succumb
to their hepatic disease (as opposed to right heart failure) if not
transplanted [15]. Other POPH patients can successfully complete
LT with pulmonary vasoactive medications, but cannot be
weaned due to continued abnormal pulmonary hemodynamics.
Pre-LT inability to reduce MPAP to less than 35 mmHg with pul-
monary vasoactive therapy disqualiﬁes patients for standard
MELD exception. Failure to reduce MPAP below 50 mmHg is con-
sidered by most centers to be a contraindication to LT or, at the
time of operation, grounds to cancel the LT procedure prior to
the abdominal incision. Although experience is limited, at this
time it seems logical that similar pulmonary hemodynamic
guidelines should be followed when living-donor-POPH trans-
plants are considered [23,24].Future considerations
With a combination of liver transplantation and pulmonary vaso-
active medications, moderate to severe pulmonary artery hyper-
tension is curable in some cases. However, two POPH issues have
evolved. First, the MELD exception is not granted under current
U.S. policy, even if there is normalization of PVR and right ventric-
ular (RV) function with pre-LT therapy if MPAP remains
>35 mmHg. The elevation in MPAP in such patients is a change3 vol. 59 j 367–374 369
Table 3. Distinguishing pulmonary hemodynamic patterns.⁄
Clinical situation  RVSP MPAP PCWP CO PVR
Portal hypertension  ↑ ↑ n ↑ n↓
HPS n↑ n↑ n ↑ n↓
POPH ↑↑↑ ↑↑↑ n↑ ↑↓ ↑↑↑
HHT (+ hepatic AVM) ↑ ↑ n↑ ↑↑ n↓
HHT (PAH)  ↑↑↑ ↑↑↑ n n↓ ↑↑↑
HHT (PAVM) ↑ ↑ n ↑ n↓
⁄Measurements by right heart catheterization.
PAH, pulmonary artery hypertension; PAVM, pulmonary arteriovenous malfor-
mations; n, normal; RVSP, right ventricular systolic pressure by transthoracic
echocardiography; MPAP, mean pulmonary artery pressure; PCWP, pulmonary
capillary wedge pressure; CO, cardiac output; PVR, pulmonary vascular
resistance.
Reviewin physiology, the result of pulmonary vasoactive therapy
increasing the existing high ﬂow state, and decreasing the
pulmonary vascular resistance to ﬂow. Normalization of RV func-
tion and PVR is an ultimate, desired goal in treating any form of
pulmonary artery hypertension and MELD exception would be
granted despite the ‘‘abnormal MPAP’’. It is hypothesized that
for those individuals, cure of POPH after LT can be obtained. How-
ever, it does remain unknown whether pulmonary hemodynamic
normalization post LT reﬂects a pathologic pulmonary vascular
cure.
Second, with the adoption of the standard MELD exception for
POPH, those with exception for this diagnosis can now be tracked
in terms of general survival though details regarding speciﬁc
therapies will not be known. Therefore, the clinical/optimal out-
come correlates of POPH post LT long-term survival need to be
identiﬁed via registry or a multicenter database approach. For
example, assessment of acute pulmonary vascular reactivity (by
different agents) and effect on PCWP pre-LT (unmasking cardio-
myopathy?) may suggest the need for speciﬁc pulmonary vasoac-
tive medications [25].Hereditary hemorrhagic telangiectasia (HHT)
Although a spectrum of hepatic vascular malformations (HVM)
exists in approximately 32–78% of HHT patients, less than 10%
are symptomatic [26]. Liver transplantation has been conducted
as a means to treat HHT-induced related HVM. These lesions
can result in ischemic biliary necrosis, intractable portal hyper-
tension and high output cardiac failure due to increased preload
that occurs as a consequence of intrahepatic arteriovenous and
arterioportal shunting [26].
Screening transthoracic echocardiography in any patient with
HHT may suggest pulmonary hypertension (i.e., right ventricular
enlargement and increased tricuspid regurgitant peak velocity). It
is important to correctly identify HHT-induced HVM causing
increased pulmonary artery pressures which invariably accompa-
nies (and likely predisposes) to high output cardiac failure. Imag-
ing of the liver (Doppler ultrasound or CT scanning) and right
heart catheterization are essential in the identiﬁcation process.
Speciﬁc pulmonary hemodynamic patterns with normal or
reduced PVR would be consistent with that scenario (Table 3).
Pulmonary vasoactive medications would not be indicated; LT
would be curative of high output cardiac failure based upon
experience to date. As a caveat, Trembath et al. [27] and Abdalla370 Journal of Hepatology 201et al. [28] have described (genetics, hemodynamics and pathol-
ogy) a form of pulmonary artery hypertension in HHT character-
ized by very high PVR, similar to what was previously known as
primary pulmonary hypertension. Right heart catheterization is
key in identifying such patients, noting that HVM were docu-
mented in some patients in both series. The role for LT in that
entity is unknown and pulmonary vasoactive therapy would
seem appropriate.
The co-existence of pulmonary and hepatic AVM does occur,
can occur in the setting of high output cardiac failure, but appears
to be uncommon (Fig. 3). Unlike successful treatment of pulmon-
ary AVM with coil embolotherapy to treat hypoxemia and pre-
vent paradoxical emboli, embolization of intrahepatic vascular
abnormalities is not advised, leading to ischemic biliary necrosis
and the need for urgent LT [26]. A recent French HHT experience
using the vascular endothelial growth factor inhibitor bev-
acizumab (biweekly injections for 2.5 months) to ameliorate the
high output state due to HVM has been favorable [29]. Six
months from the initiation of therapy, mean cardiac index
improved (lessened) in 20/24 patients, mean systolic pulmonary
pressure decreased (PVR not measured) and a signiﬁcant reduc-
tion in the severity of epistaxis was documented. Subsequent
need or outcome of LT was not reported.
The published outcomes of LT in the setting of high output
cardiac failures due to HHT-induced HVM are favorable [30].
From the European Liver Transplant Registry, cardiac function
improved in 18 (75%) of 24 HHT patients transplanted for such
cardiac failure [31]. Dupuis-Girod et al. [32] reported 10 HHT
patients in a single-center study, transplanted for high output
cardiac failure with normalization of hemodynamics (by echo
and/or right heart catheterization and signiﬁcant improvement
in epistaxis). In these studies, the 5-year patient survival ranged
from 82.5% to 92%. Recurrence of HVM in two patients several
years after LT has been reported [33].
There are no formal MELD exception criteria for any pulmon-
ary manifestation of HHT due to the rarity of this condition, but
currently, centers may request from their respective RRB, a MELD
exception score of 22 to treat high output cardiac failure as per
the recommendation of the MELD exception Study Group [34].
Pulmonary hemodynamic patterns that distinguish and charac-
terize HPS, POPH, and HHT patterns are summarized in Table 3.
Future considerations
Pulmonary hypertension-right heart failure due to HHT can be
safely accomplished and heart failure reversed. The development
of high-output cardiac failure due to hepatic AVM is life-threat-
ening; the relationship between life threatening epistaxis and
hepatic involvement in HHT is unknown. The improvement in
epistaxis post LT for high output failure now has been docu-
mented. The risk/beneﬁt of LT in preventing deadly hemorrhagic
complications of HHT warrants further consideration.Refractory hepatic hydrothorax (HH)
Occurring in approximately 5–12% of those with advanced liver
disease, HH (>500 pleural ﬂuid) is due to the formation of ascitic
ﬂuid that is drawn into the hemithorax due to pressure gradient
that occurs with inspiration and microscopic passages through
the hemidiaphragm [35].3 vol. 59 j 367–374
Pre-liver transplant Post-liver transplantA B
Fig. 3. Pre and post-transplant CXR in HHT patient with high-output cardiac
failure. (A) Pre-transplant embolization of pulmonary arteriovenous malforma-
tion in the left lower lobe was observed. (B) At 24 months post liver transplant,
pulmonary venous hypertension and cardiac failure resolved, but cardiomegaly
was still present.
JOURNAL OF HEPATOLOGYTreatment of HH is based upon minimizing ascitic ﬂuid pro-
duction with salt restriction and diuresis usually accomplished
with a combination of furosemide and spironolactone. Failure
to control symptomatic HH with sodium restriction (<2 g/day),
tolerable amounts of diuretic (160 mg/day furosemide and
400 mg/day spironolactone, or repeated thoracentesis), deﬁnes
the concept of refractory hepatic hydrothorax (RHH) [35].
Transjugular intrahepatic portosystemic shunting (TIPS) can
result in complete, partial or no resolution of RHH. Complications,
survival after TIPS, and expectations for subsequent LT are factors
to be considered when the decision is made to treat RHH. Dhan-
asekaran et al. [36] reported 73 patients who had undergone TIPS
for RHH with varying clinical response at 1 month post-TIPS:
complete (59%), partial (21%) and none (21%). Transplant
frequency and outcomes were not reported. The 1 and 5-year
survivals post-TIPS were 48% and 15%, respectively. Increased
pre-TIPS creatinine and MELD >15 had worse survival. Jeffries
et al. [37] reported 4/12 TIPS patients with RHH who underwent
LT. Each required some form of post LT pleural drainage and
3 had favorable long-term post LT outcome (minimal to no pleu-
ral effusion at 2 years). One had recurrent ascites and pleural
effusion persisting for 3 years post LT.
The outcome of HH (refractory or not) following LT is very
favorable. Xiol et al. [38] reported 28 HH patients (no deﬁnition
of ﬂuid amount given) vs. 56 transplanted controls. Five patients
were considered refractory; no patient received TIPS or had chest
tube drainage. HH persisted in 36% of patients at one month post
LT, but had resolved in all patients within 3 months of transplant.
Serste et al. [39] described no outcome differences in HH (esti-
mated pleural ﬂuid >500 cc by chest radiograph) compared to
those with tense ascites and no HH (both groups had n = 11);
Nine patients were considered to have RHH pre-LT; 73% required
pre-LT thoracentesis (55% needed repeat taps) and none had TIPS
placed pre-LT.
Pulmonary hypertension is considered a contraindication to
TIPS. This concern is based upon increased preload/cardiac out-
put acutely following TIPS that could worsen pre-existing right
ventricular dysfunction. However, there are no studies that
deﬁne at what echo pressures or degree of right ventricular dys-
function may portend hemodynamic collapse following TIPS
placement. At our institution, transthoracic echocardiography
demonstrating RV systolic pressure >50 mmHg and/or moderateJournal of Hepatology 201to severe dilation of the RV would be a contraindication to non-
emergent TIPS.
There are no data to suggest an increased mortality on the LT
waitlist in the setting of RHH or poor LT outcomes; therefore
MELD exception for this entity (regardless of the use or not of
TIPS) is not the current OPTN policy.Future considerations
Distinguishing RHH-LT outcomes by the presence or absence of
concomitant arterial hypoxemia might be an area of clinical
investigation that could impact LT priority.Advanced chronic obstructive pulmonary disease (COPD)
In the largest prospective study to date, smoking history in LT
candidates (373 patients at 7 LT centers) was common (60%)
with 27% considered current smokers [40]. Clinically signiﬁcant
COPD (FEV1/FVC <70% due to bronchitis and/or centrilobular,
upper lobe predominance emphysema) was uncommon (67/
363; 18%). A previous diagnosis of COPD prior to LT evaluation
did not exist in 80% of those patients. Of those listed for LT with
pulmonary function testing (204/373), severe COPD (30% <FEV1%
predicted <50%) occurred in 11%. No patient had FEV1% <30%. LT
was conducted in 30% of those listed. Risk of death and outcomes
(median follow-up 601 days post LT) were not affected by the
existence or severity of COPD [40]. However, no data were pre-
sented to describe duration of intubation/mechanical ventilation,
length of hospital stay or other morbidities, so post LT morbidi-
ties associated with severe COPD remain speculative.
There are no data to justify granting MELD exception for
smoking-related COPD, since it is not caused by liver disease or
resolved by LT. There are no speciﬁc guidelines as to which COPD
patients are too advanced to preclude safe LT. Published 5-year
survivals for patients, liver disease notwithstanding, with severe
COPD (FEV1 <50% predicted) range from 50–70%, worse (24–30%)
in those with FEV1 <30% predicted and much worse when COPD
exacerbation requires non-invasive ventilation (mean FEV1 37%
predicted with 2 and 5-year survivals 52% and 26%, respectively
[41,42].
Alpha-1 antitrypsin deﬁciency (AATD), especially the ZZ geno-
type, can result in signiﬁcant pathophysiology due to accumula-
tion/polymerization/abnormal metabolism of the dysfunctional
alpha-1 protein in hepatocytes [43]. Unexpected signiﬁcant liver
disease in ZZ-lung patients (n = 57; 24 with liver biopsies; 11 had
severe ﬁbrosis or cirrhosis) has recently been described [44]. Such
accumulation results in circulating serum deﬁciency, leading to
AATD-related emphysema (panlobular, lower lobe predomi-
nance), since neutrophil elastase is no longer neutralized and
destroys alveolar supporting structures [44]. ZZ patients without
clinically obvious hepatic dysfunction can have an accelerated
annual decline in FEV1 and increased mortality compared to con-
trols [43]. In ZZ or SZ LT candidates, the true frequency and
degree of abnormal FEV1% predicted (the most common pulmon-
ary function parameter followed in such patients) are speculative
since pre-LT pulmonary function tests are not often accom-
plished, yet may be surprisingly abnormal [45].
Jain et al. [46] reported the effect of LT on pulmonary function
(n = 7) and 3/7 were considered to be severely deﬁcient pre LT
(no alpha-1 genotypes given). The pre LT FEV1% predicted was3 vol. 59 j 367–374 371
Review
abnormal in 2 out of three patients (51% and 63%) and had not
changed at only 12 and 8 months post LT, respectively. Carey
et al. [45] have reported longer follow-up in 33 ZZ and 17 SZ LT
patients, describing pre-LT FEV1% in 11/50, with 7/11 experienc-
ing decline in FEV1% (median of 14%; range 5–29%) at a median of
34 months (range 13–126) post LT. Kemmer et al. [47] described
1, 3, and 5 year survivals post LT of 89%, 85%, and 83% for adults
(n = 406) from the UNOS database (1995–2004), but it was
unclear if data were restricted to ZZ or included MZ and other
alpha-1 phenotypes, an important distinction. It is expected
and noted that the hepatic allograft (with a normal alpha-1 geno-
type) will result in normalization of the circulating alpha-1 pro-
tein level [45,46]. The long-term pulmonary changes following
LT, especially in the pediatric age group, are unknown [48].
For similar reasons stated regarding other causes of COPD in
terms of resolution post LT, MELD exception for AATD-related
emphysema is not recommended at this time. However, since
ZZ and SZ liver disease can directly affect lung function change,
additional considerations are suggested below.
Future considerations
The severe deﬁciency of circulating AAT protein can resolve, but
not necessarily stabilize lung function. Consistent assessment of
pulmonary function pre and post LT is needed. In adults and chil-
dren, an untested hypothesis is whether LT can halt or slow the
accelerated lung function decline that exists in ZZ and/or SZ
patients. Could progressive pulmonary decline be an indication
for earlier LT in adults with severe AAT deﬁciency? Could LT obvi-
ate the need for life-long AAT replacement therapy to prevent
further lung injury (weekly or biweekly pooled plasma protein
infusions) that now approaches $100,000 per year?201220102009
A B C
Fig. 4. Resolution of severe HPS (standing PaO2 mmHg: 46 on room air, 106 on
100% inspired oxygen) with liver transplant; followed by progression
idiopathic pulmonary ﬁbrosis and subsequent lung single transplant. (A)
Pre-liver transplant cxr; (B) 14 month post-liver transplant cxr showing IPF
progression (PaO2); (C) 20 month post-lung transplant cxr.Pulmonary nodules
The detection of new pulmonary nodules (solitary or multiple)
complicates the decision to proceed to LT in the setting of hepato-
cellular carcinoma (HCC) [49]. Metastatic pulmonary lesions,
biopsy proven, would be a contraindication to LT. Biopsy of suspi-
cious lesions must be obtained since computed tomography (CT)
and positron emission tomography-ﬂuorodeoyglucose (PET-FDG)
scanning can lead to images strongly suggestive of malignancy,
yet biopsy results may document treatable granulomatous infec-
tions such Cryptococcus, Mycobacterium tuberculosis orMycobacte-
rium avium complex [49,50]. The importance of FDG PET/CT
scanning in the setting of HCC does facilitate the identiﬁcation of
multiple lesions, as well as provide a road map for possible
endobronchial ultrasound guidance for lymph node needle aspira-
tions. A recentmeta-analysis of 239 cases from3 studies reported a
77% sensitivity and 98% speciﬁcity in identifying pulmonary
metastases in the presence of newly diagnosed HCC [51].
Multidetector CT scanning remains more sensitive than FDG
PET/CT scanning to identify and follow nodules that are less than
8–10 mm [52]. Small nodules (<10 mm) should be followed post
LT, especially in the setting of high grade HCC and those tumors
exceeding Milan criteria [53]. Despite the best pre-LT efforts to
detect pulmonary metastases, if such do arise post LT, surgical
excision can be undertaken with resultant long-term survival.
Hwang et al. [54] reported a 44.7% 5-year post LT, post resection
survival in 23 HCC patients.372 Journal of Hepatology 201The occurrence of operable, early lung cancer in the setting of
cirrhosis is uncommon (33/876–3.9% in the most recent surgical
series), and offers yet another reason to speciﬁcally identify the
correct etiology of a new pulmonary nodule associated with cur-
rent or past smoking history [55].
Future considerations
Lung resection for metastatic hepatocellular carcinoma post LT is
achievable with acceptable long-term survival and should be
considered in highly selected cases.Interstitial lung disease (ILD)
Rarely, idiopathic pulmonary ﬁbrosis (IPF) or non-speciﬁc inter-
stitial lung disease (ILD) may complicate primary biliary cirrho-
sis, autoimmune hepatitis or hepatitis C [56]. These entities
result in reduced total lung capacity (TLC <80% predicted),
reduced FVC and normal expiratory airﬂow (FEV1/FVC >70%).
They may contribute to arterial hypoxemia and co-exist with
HPS [57]. Herein lies the value of attaining 99mTcMAA lung-brain
perfusion scanning to discern the actual cause of hypoxemia; the
brain uptake in any ILD should be normal (<6%) since abnormal
ventilation in the setting of normal perfusion is the primary cause
of hypoxemia.
With the possible exception of lymphocytic interstitial pneu-
monitis associatedwith PBC, ILD is not expected to reverse follow-
ing LT and may progress despite the use of immunosuppression.
Successful single lung transplantation has been accomplished in
a patient with severe HPS and mild IPF in which the former
resolved and the latter progressed following LT (Fig. 4).
Despite the common occurrence of restrictive lung physiology
in advanced liver diseases (usually due to HH or ascites), biopsy
proven ILD as a cause of restriction appears uncommon. The
reversibility of ILD, especially IPF, is rarely observed and lung
transplant is the current treatment of choice. Moderate to severe
restriction due to IPF can be considered a contraindication to LT.
In the case of IPF, the median survival is 2–4 years and 5-year
survival ranges from 20% to 40% without lung transplant [58].
There are no current data to support ILD-related MELD exception
when any degree or form of ILD complicates advanced liver
disease.3 vol. 59 j 367–374
Table 4. Pulmonary contraindications, indications and MELD exception for liver transplant.
Contraindication Indication Current MELD exception policy (3.6.4.5)
HPS No; unless co-morbidities Yes Yes; PaO2 <60 mmHg; COPD excluded
POPH MPAP >50 mmHg* Yes (?) Yes; MPAP <35 mmHg and PVR <400 dynes.s.cm-5
HHT If PAH untreated HAVM Can petition RRB due to high output failure; no policy
HH (refractory) No No supportive data No policy
COPD If severe (?); current smokers No supportive data No policy (AATD should be studied)
Nodules If metastatic HCC No supportive data MELD exception currently exists for HHC
ILD If severe No supportive data No data to suggest ILD can reverse or be stabilized with LT
HPS, hepatopulmonary syndrome; POPH, portopulmonary hypertension; HHT, hereditary hemorrhagic telangiectasia; HCC, hepatocellular carcinoma; HH, hepatic
hydrothorax; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung diseases; PAH, pulmonary artery hypertension.
⁄MPAP, mean pulmonary artery hypertension (criteria with or without pulmonary vasoactive therapy); PVR, pulmonary vascular resistance.
HAVM, hepatic arteriovenous malformations; RRB, regional review boards.
JOURNAL OF HEPATOLOGYFuture considerations
The clinical course of ILD, especially IPF, following LT, warrants
further studies. In highly selected cases, sequential liver-
then-lung transplant can be successfully accomplished in the
setting of progressive IPF post LT.
Key Points
• Hepatopulmonary syndrome is an indication for liver
transplant; severe hypoxemia is reversible post-
transplant with support and time
• Severe portopulmonary hypertension is a 
contraindication to transplant, yet potentially “curable” if
medical treatment can significantly improve pulmonary
hemodynamics and right heart function pre-transplant
• Hereditary hemorrhagic telangiectasia-related high
output heart failure due to intrahepatic arteriovenous
malformations can resolve post-transplant
• Refractory hepatic hydrothorax does not impact post-
transplant outcome and has yet to merit higher priority
for transplant
• Whether development or progression of pulmonary
emphysema due to α-1 antitrypsin deficiency (ZZ or SZ
genotypes) may be halted by liver transplant is a valid
research questionConclusions
Pulmonary priorities for LT, as deﬁned by MELD exception poli-
cies, have been evolving over the years and the current policies
are summarized in Table 4. Future implications regarding each
of these pulmonary-liver transplant issues can be expected to
further evolve. To facilitate our understanding of clinical pulmon-
ary–liver transplant advances, the expanded roles of registries
and multicenter databases cannot be understated. From such col-
lective experiences, we can hopefully reﬁne and better character-
ize the current pulmonary contraindications, as well as possibly
expand indications for LT.Journal of Hepatology 201Conﬂict of interest
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